1. Analysis of the progression-free survival of CLL patients who received first-line bendamustine-rituximab therapy depending on the elimination rate of the minimum residual disease and mutational status IGHV genes. (October 2019) Authors: Miroliubova, I.; Stadnik, E.; Strugov, V.; Virz, Y.; Nikulina, T.; Tolstopiatova, E.; Rumyantsev, A.; Chatalava, T.; Timofeeva, N.; Zaritskey, A. Journal: Leukemia research Issue: Volume 85(2019)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗